Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) have been given a consensus recommendation of “Hold” by the ten ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $2.45.

RGLS has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research note on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Leerink Swann started coverage on shares of Regulus Therapeutics in a research report on Friday. They set an “outperform” rating and a $2.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th.

Large investors have recently modified their holdings of the stock. Quantitative Investment Management LLC purchased a new position in shares of Regulus Therapeutics in the 2nd quarter worth about $103,000. GSA Capital Partners LLP purchased a new position in shares of Regulus Therapeutics in the 2nd quarter worth about $139,000. Royal Bank of Canada boosted its holdings in shares of Regulus Therapeutics by 12.1% in the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 19,934 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of Regulus Therapeutics in the 3rd quarter worth about $347,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Regulus Therapeutics by 189.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after buying an additional 240,890 shares during the last quarter. 59.39% of the stock is currently owned by institutional investors.

Regulus Therapeutics (NASDAQ RGLS) opened at $1.18 on Friday. Regulus Therapeutics has a 12 month low of $0.79 and a 12 month high of $2.60. The firm has a market cap of $124.75, a PE ratio of -0.87 and a beta of 1.55. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77.

ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics Inc (RGLS) Given Average Rating of “Hold” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/05/regulus-therapeutics-inc-rgls-given-average-rating-of-hold-by-analysts.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.